KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
16 Février 2024 - 12:30PM
Business Wire
– Late-breaking phase 3 data for KONFIDENT
trial on Sunday, February 25, 2024 –
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of oral, small molecule protease inhibitors,
today announced the acceptance of multiple abstracts at the 2024
American Academy of Allergy, Asthma & Immunology (AAAAI) Annual
Meeting taking place in Washington, DC from February 23-26.
The following presentations will take place on Saturday,
February 24, 2024 from 9:45 - 10:45 am ET in the Convention Center,
Level 2, Hall D.
- Characteristics of Hereditary Angioedema Attacks Among
Long-Term Prophylaxis Users (#215): Bob Geng, Vibha Desai,
Julie Ulloa, Sherry Danese, Shawn Czado, Paul K. Audhya,
Timothy Craig. Results shared as an
oral poster presentation and Q&A
- Delayed On-demand Treatment of Hereditary Angioedema
Attacks: Patient Perceptions and Associated Barriers (#216):
Sandra Christiansen, Maeve O’Connor,
Julie Ulloa, Sherry Danese, Vibha Desai, Shawn Czado, Paul Audhya,
Paula Busse. Results shared as an oral poster presentation and
Q&A
- Anxiety Associated with On-Demand Treatment for Hereditary
Angioedema (HAE) Attacks (#257): James
Wedner, Cristine Radojicic, Julie Ulloa, Sherry Danese,
Vibha Desai, Shawn Czado, Paul Audhya, Sandra Christiansen. Results
shared as an oral poster presentation and Q&A
- Anxiety Associated with Refilling On-demand Therapy for HAE
Attacks Contributes to Treatment Delay and Non-Treatment
(#258): Daniel F. Soteres, Anete S. Grumach, Sally van Kooten,
Neil Malloy, Markus Heckmann, Julie Ulloa, Autumn Burnette. Results shared as an oral poster
presentation and Q&A
- Characterizing the Negative Impact of Delayed On-Demand
Treatment of HAE Attacks (#260): Princess
Ogbogu, Hilary Longhurst, Sally van Kooten, Neil Malloy,
Markus Heckmann, Julie Ulloa, Ricardo Zwiener. Results shared as an
oral poster presentation and Q&A
- The Impact of On-demand Treatment on Quality of Life of
People with HAE (#265): Paula
Busse, Bob Geng, Sally van Kooten, Neil Malloy, Markus
Heckmann, Julie Ulloa, Douglas H. Jones. Results shared as an oral
poster presentation and Q&A
- Characterizing the Perspective of Patients with HAE on
Prophylactic Treatment (#270): Stephen
Betschel, Cristine Radojicic, Sally van Kooten, Neil Malloy,
Markus Heckmann, Julie Ulloa, William Lumry. Results shared as an
oral poster presentation and Q&A
- Treatment Patterns of Patients Requiring Redosing of an
On-demand Treatment After the Return of an HAE Attack (#284):
Constance Katelaris, Michael Manning,
Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa,
William Lumry. Results shared as an oral poster presentation and
Q&A
The following late-breaking presentation will take place on
Sunday, February 25, 2024 from 9:45 - 10:45 am ET in the Convention
Center, Level 2, Hall D.
- Sebetralstat for On-demand Treatment of Hereditary
Angioedema Attacks: Results of the Double-blind, Placebo-controlled
Phase 3 KONFIDENT Trial (L45): Marc
Riedl, Emel Ayg�ren-Pürsün, William Lumry, Henriette Farkas,
Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith,
Christopher Yea, Paul K. Audhya, Jonathan Bernstein, Marcus Maurer,
Danny Cohn
Links to all posters and presentations can be found on the
KalVista website under “Publications”.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista disclosed positive phase 3 data
for the KONFIDENT trial for its oral, on-demand therapy
sebetralstat in February 2024. The Company anticipates submitting a
new drug application to the U.S. FDA for sebetralstat in the first
half of 2024 and expects to file for approval in Europe and Japan
later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor
program represents a new generation of therapies that may further
improve the treatment for people living with HAE and other
diseases.
For more information about KalVista, please visit
www.kalvista.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and results, our ability to commence clinical
studies or complete ongoing clinical studies, including our
KONFIDENT-S trial, and to obtain regulatory approvals for
sebetralstat and other candidates in development, the success of
any efforts to commercialize sebetralstat, the ability of
sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2023, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240216185634/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024